Literature DB >> 18922486

Rotavirus vaccines: viral shedding and risk of transmission.

Evan J Anderson1.   

Abstract

Rotavirus causes gastroenteritis in almost all children by 5 years of age. Immunity to rotavirus is incomplete, with potential for recurrent infections occurring throughout life. Live rotavirus vaccines have been developed for the protection of children from severe wildtype rotavirus infections. Transmission of vaccine virus strains from vaccinated children to unvaccinated contacts harbours the potential for herd immunity, but also the risk of vaccine-derived disease in immunocompromised contacts. A review of rotavirus vaccine prelicensure studies shows that viral shedding and transmission were higher with the old tetravalent rhesus rotavirus vaccine than with the current human attenuated monovalent rotavirus vaccine and the pentavalent bovine-human reassortant vaccine. Immunocompromised contacts should be advised to avoid contact with stool from the immunised child if possible, particularly after the first vaccine dose for at least 14 days. Since the risk of vaccine transmission and subsequent vaccine-derived disease with the current vaccines is much less than the risk of wildtype rotavirus disease in immunocompromised contacts, vaccination should be encouraged.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922486     DOI: 10.1016/S1473-3099(08)70231-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  38 in total

Review 1.  Vaccination against infection in patients with multiple sclerosis.

Authors:  Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

Review 2.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

3.  Monitoring Shedding of Five Genotypes of RotaTeq Vaccine Viruses by Genotype-Specific Real-Time Reverse Transcription-PCR Assays.

Authors:  Yuki Higashimoto; Masaru Ihira; Yu Miyazaki; Ayumi Kuboshiki; Sayaka Yoshinaga; Hiroyuki Hiramatsu; Ryota Suzuki; Masafumi Miyata; Hiroki Miura; Satoshi Komoto; Jun Yukitake; Koki Taniguchi; Yoshiki Kawamura; Tetsushi Yoshikawa
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

4.  Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine.

Authors:  Daniel Cowley; Karen Boniface; Nada Bogdanovic-Sakran; Carl D Kirkwood; Julie E Bines
Journal:  Hum Vaccin Immunother       Date:  2017-05-08       Impact factor: 3.452

Review 5.  Vaccination strategies in patients with IBD.

Authors:  Javier P Gisbert; María Chaparro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

6.  One-step Quantitative RT-PCR Assays for Detecting, Genotyping and Differentiating Wild-Type Group a Rotaviruses and Vaccine (Rotarix® and RotaTeq®) Strains in Stool Samples.

Authors:  Rashi Gautam; Michael D Bowen
Journal:  J Vaccines Vaccin       Date:  2016-09-26

Review 7.  Rotaviruses: from pathogenesis to vaccination.

Authors:  Harry B Greenberg; Mary K Estes
Journal:  Gastroenterology       Date:  2009-05-07       Impact factor: 22.682

8.  Rotavirus NSP1 protein inhibits interferon-mediated STAT1 activation.

Authors:  Adrish Sen; Lusijah Rott; Nguyen Phan; Gourab Mukherjee; Harry B Greenberg
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

9.  Vaccine-acquired rotavirus in infants with severe combined immunodeficiency.

Authors:  Niraj C Patel; Paula M Hertel; Mary K Estes; Maite de la Morena; Ann M Petru; Lenora M Noroski; Paula A Revell; I Celine Hanson; Mary E Paul; Howard M Rosenblatt; Stuart L Abramson
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

10.  Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine:a phase I clinical trial.

Authors:  Zhi-Wei Wu; Qing-Liang Li; Hai-Song Zhou; Kai Duan; Zhao Gao; Xin-Jiang Zhang; Zhi-Jun Jiang; Zhi-Yong Hao; Fei Jin; Xuan Bai; Qi Li; Ge-Lin Xu; Yu-Liang Zhao; Xiao-Ming Yang
Journal:  Hum Vaccin Immunother       Date:  2021-02-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.